Business
AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)-- AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana
About this update from Kalaris Therapeutics, Inc.
[{"type":"text","content":" WALTHAM, Mass.--(BUSINESS WIRE)--\nAlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York City, NY on Tuesday, November 28, 2023 at 10:00 a.m. ET.\n\n\nA live webcast and archived replay of the presentation will be available on the Investors & Press section of the AlloVir website at https://ir.allovir.com.\n\n\nAbout AlloVir\n\n\nAlloVir is a leading late-clinical stage cell therapy company focused on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company's innovative and proprietary technology platform leverages off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir's technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information, visit www.allovir.com or follow us on Twitter/X or LinkedIn.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20231116711808/en/\n\nMedia and Investor:\[email protected]\n\n\nSource: AlloVir, Inc.","length":3725,"tagName":"div"}]